Works by Sobue, Satoshi


Results: 22
    1

    Poor Tolerability of Lenvatinib in Elderly Patients with Advanced Hepatocellular Carcinoma after Disease Progression following First-Line Atezolizumab Plus Bevacizumab: A Multicenter Study.

    Published in:
    Oncology, 2025, v. 103, n. 4, p. 311, doi. 10.1159/000541455
    By:
    • Kato, Daisuke;
    • Suzuki, Takanori;
    • Matsuura, Kentaro;
    • Okayama, Kohei;
    • Okumura, Fumihiro;
    • Nagura, Yoshihito;
    • Sobue, Satoshi;
    • Hayashi, Katsumi;
    • Kusakabe, Atsunori;
    • Hasegawa, Izumi;
    • Matoya, Sho;
    • Mizoshita, Tsutomu;
    • Kimura, Yoshihide;
    • Kondo, Hiromu;
    • Ozasa, Atsushi;
    • Kawamura, Hayato;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke;
    • Kataoka, Hiromi
    Publication type:
    Article
    2

    Prognostic Nutritional Index after Introduction of Atezolizumab with Bevacizumab Predicts Prognosis in Advanced Hepatocellular Carcinoma: A Multicenter Study.

    Published in:
    Oncology, 2024, v. 102, n. 8, p. 676, doi. 10.1159/000536367
    By:
    • Suzuki, Takanori;
    • Matsuura, Kentaro;
    • Suzuki, Yuta;
    • Okumura, Fumihiro;
    • Nagura, Yoshihito;
    • Sobue, Satoshi;
    • Kato, Daisuke;
    • Kusakabe, Atsunori;
    • Koguchi, Hiroki;
    • Hasegawa, Izumi;
    • Matoya, Sho;
    • Miyaki, Tomokatsu;
    • Kimura, Yoshihide;
    • Tanaka, Yoshito;
    • Kondo, Hiromu;
    • Ozasa, Atsushi;
    • Kawamura, Hayato;
    • Kuno, Kayoko;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke
    Publication type:
    Article
    3
    4
    5

    Helicobacter pylori eradication decreases the expression of glycosylphosphatidylinositol-anchored complement regulators, decay-accelerating factor and homologous restriction factor 20, in human gastric epithelium.

    Published in:
    Journal of Gastroenterology & Hepatology, 2005, v. 20, n. 9, p. 1344, doi. 10.1111/j.1440-1746.2005.03876.x
    By:
    • Joh, Takashi;
    • Sasaki, Makoto;
    • Kataoka, Hiromi;
    • Tanida, Satoshi;
    • Itoh, Keisuke;
    • Kondo, Yutaka;
    • Ogasawara, Naotaka;
    • Oshima, Tadayuki;
    • Okada, Noriko;
    • Ohara, Hirotaka;
    • Sano, Hitoshi;
    • Nakao, Haruki;
    • Sobue, Satoshi;
    • Itoh, Makoto
    Publication type:
    Article
    6
    7
    8

    Serum interleukin‐6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis.

    Published in:
    Journal of Gastroenterology & Hepatology, 2024, v. 39, n. 10, p. 2158, doi. 10.1111/jgh.16672
    By:
    • Suzuki, Takanori;
    • Matsuura, Kentaro;
    • Suzuki, Yuta;
    • Okumura, Fumihiro;
    • Nagura, Yoshihito;
    • Sobue, Satoshi;
    • Matoya, Sho;
    • Miyaki, Tomokatsu;
    • Kimura, Yoshihide;
    • Kusakabe, Atsunori;
    • Narahara, Satoshi;
    • Tokunaga, Takayuki;
    • Nagaoka, Katsuya;
    • Murakami, Shuko;
    • Inoue, Takako;
    • Kuroyanagi, Keita;
    • Kawamura, Hayato;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke;
    • Kataoka, Hiromi
    Publication type:
    Article
    9
    10
    11

    Prognostic indicators estimated by <sup>99m</sup>Tc-GSA in acute liver damage

    Published in:
    Hepatology Research, 2005, v. 31, n. 3, p. 153, doi. 10.1016/j.hepres.2004.11.013
    By:
    • Monoe, Takashi;
    • Nomura, Tomoyuki;
    • Nakao, Haruhisa;
    • Sobue, Satoshi;
    • Mizuno, Yaichi;
    • Nojiri, Syunsuke;
    • Kanematsu, Takayoshi;
    • Senda, Katsuhiro;
    • Ohmi, Hitoshi;
    • Ohara, Hirotaka;
    • Joh, Takashi;
    • Itoh, Kazuyuki;
    • Itoh, Makoto
    Publication type:
    Article
    12

    Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis.

    Published in:
    Cancer Medicine, 2024, v. 13, n. 1, p. 1, doi. 10.1002/cam4.6876
    By:
    • Takanori Suzuki;
    • Kentaro Matsuura;
    • Yuta Suzuki;
    • Fumihiro Okumura;
    • Yoshihito Nagura;
    • Satoshi Sobue;
    • Sho Matoya;
    • Tomokatsu Miyaki;
    • Yoshihide Kimura;
    • Atsunori Kusakabe;
    • Satoshi Narahara;
    • Takayuki Tokunaga;
    • Katsuya Nagaoka;
    • Keita Kuroyanagi;
    • Hayato Kawamura;
    • Kayoko Kuno;
    • Kei Fujiwara;
    • Shunsuke Nojiri;
    • Hiromi Kataoka;
    • Yasuhito Tanaka
    Publication type:
    Article
    13
    14

    Neutrophil‐to‐lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.

    Published in:
    Hepatology Research, 2025, v. 55, n. 6, p. 883, doi. 10.1111/hepr.14189
    By:
    • Suzuki, Takanori;
    • Matsuura, Kentaro;
    • Sobue, Satoshi;
    • Kato, Daisuke;
    • Hayashi, Katsumi;
    • Kondo, Hiromu;
    • Anbe, Kaiki;
    • Mizoshita, Tsutomu;
    • Okayama, Kohei;
    • Okumura, Fumihiro;
    • Kimura, Yoshihide;
    • Ozasa, Atsushi;
    • Inada, Hiroki;
    • Tokunaga, Takayuki;
    • Narahara, Satoshi;
    • Kawamura, Hayato;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke;
    • Kataoka, Hiromi;
    • Tanaka, Yasuhito
    Publication type:
    Article
    15

    The neutrophil‐to‐lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.

    Published in:
    Hepatology Research, 2023, v. 53, n. 6, p. 511, doi. 10.1111/hepr.13886
    By:
    • Matoya, Sho;
    • Suzuki, Takanori;
    • Matsuura, Kentaro;
    • Suzuki, Yuta;
    • Okumura, Fumihiro;
    • Nagura, Yoshihito;
    • Sobue, Satoshi;
    • Kuroyanagi, Keita;
    • Kusakabe, Atsunori;
    • Koguchi, Hiroki;
    • Hasegawa, Izumi;
    • Miyaki, Tomokatsu;
    • Tanaka, Yoshito;
    • Kondo, Hiromu;
    • Kimura, Yoshihide;
    • Ozasa, Atsushi;
    • Kawamura, Hayato;
    • Kuno, Kayoko;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke
    Publication type:
    Article
    16

    Outcome of nucleos(t)ide analog cessation in patients with treatment for prevention of or against hepatitis B virus reactivation.

    Published in:
    Hepatology Research, 2023, v. 53, n. 4, p. 289, doi. 10.1111/hepr.13864
    By:
    • Suzuki, Takanori;
    • Matsuura, Kentaro;
    • Urakabe, Kenji;
    • Okumura, Fumihiro;
    • Kawamura, Hayato;
    • Sobue, Satoshi;
    • Matoya, Sho;
    • Miyaki, Tomokatsu;
    • Kimura, Yoshihide;
    • Kato, Daisuke;
    • Kusakabe, Atsunori;
    • Tanaka, Yoshito;
    • Ozasa, Atsushi;
    • Nagura, Yoshihito;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke;
    • Hagiwara, Shinya;
    • Kusumoto, Shigeru;
    • Inoue, Takako;
    • Tanaka, Yasuhito
    Publication type:
    Article
    17
    18
    19
    20
    21
    22

    Adult-onset Still's Disease (AOSD) with Gastrointestinal Lesions.

    Published in:
    Internal Medicine, 2024, v. 63, n. 24, p. 3317, doi. 10.2169/internalmedicine.3412-23
    By:
    • Takahito Harada;
    • Yoshikazu Hirata;
    • Hayato Kawamura;
    • Yuki Yamamoto;
    • Yuka Kobayashi;
    • Daisuke Kumai;
    • Akihisa Adachi;
    • Yoshihito Nagura;
    • Hirokazu Ikeuchi;
    • Noriyuki Hayashi;
    • Hiroki Takada;
    • Satoshi Sobue;
    • Megumi Yoshida
    Publication type:
    Article